(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Cabaletta Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CABA's revenue for 2027 to be $9,373,345,795, with the lowest CABA revenue forecast at $9,373,345,795, and the highest CABA revenue forecast at $9,373,345,795. On average, 3 Wall Street analysts forecast CABA's revenue for 2028 to be $11,169,188,154, with the lowest CABA revenue forecast at $1,683,632,364, and the highest CABA revenue forecast at $29,249,856,007.
In 2029, CABA is forecast to generate $33,203,738,772 in revenue, with the lowest revenue forecast at $12,142,414,496 and the highest revenue forecast at $54,265,063,049.